Etodolac and the risk of acute pancreatitis
Objective: The aim of this study was to explore the association between etodolac use and acute in Taiwan. Design: We designed a case-control study using the database of Taiwan’s National Health Insurance. Subjects: In all, 7577 subjects aged 20 years or older with newly diagnosed acute pancr...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Medical University
2017-03-01
|
Series: | BioMedicine |
Subjects: | |
Online Access: | https://doi.org/10.1051/bmdcn/2017070104 |
id |
doaj-f2afec6859d84d28a0106132827fcc8a |
---|---|
record_format |
Article |
spelling |
doaj-f2afec6859d84d28a0106132827fcc8a2020-11-25T03:43:49ZengChina Medical UniversityBioMedicine2211-80392017-03-0171410.1051/bmdcn/2017070104bmdcn2017070104Etodolac and the risk of acute pancreatitisLiao Kuan-FuCheng Kao-ChiLin Cheng-LiLai Shih-WeiObjective: The aim of this study was to explore the association between etodolac use and acute in Taiwan. Design: We designed a case-control study using the database of Taiwan’s National Health Insurance. Subjects: In all, 7577 subjects aged 20 years or older with newly diagnosed acute pancreatitis were defined as cases, and 27032 sex-matched and age-matched subjects without acute pancreatitis were defined as controls. The period considered for this study was from 1998 to 2011. For the study, never having used etodolac is defined as a subject never receiving a prescription for etodolac. Active use of etodolac is defined as a subject receiving at least 1 prescription for etodolac within 7 days of the date of their being diagnosed with acute pancreatitis. Non-active use of etodolac is defined as a subject not receiving a prescription for etodolac within 7 days but receiving at least 1 prescription for etodolac ≥ 8 days before the date of their being diagnosed with acute pancreatitis. Main outcome measure: The association between etodolac use and acute pancreatitis was estimated by using the multivariable unconditional logistic regression model. Results: After correcting for covariates, the adjusted odds ratio of acute pancreatitis was 3.78 for subjects with active use of etodolac (95% confidence interval 1.11, 12.9), compared with subjects who never used etodolac. The adjusted odds ratio decreased to 1.18 for subjects with non-active use of etodolac (95% confidence interval 0.38, 3.67), but that was without statistical significance. Conclusion: There could be an association between active use of etodolac and acute pancreatitis. Clinicians should take into account the possibility of etodolac-associated acute pancreatitis when patients currently using etodolac present with acute pancreatitis with an unknown cause.https://doi.org/10.1051/bmdcn/2017070104Acute pancreatitisEtodolac |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liao Kuan-Fu Cheng Kao-Chi Lin Cheng-Li Lai Shih-Wei |
spellingShingle |
Liao Kuan-Fu Cheng Kao-Chi Lin Cheng-Li Lai Shih-Wei Etodolac and the risk of acute pancreatitis BioMedicine Acute pancreatitis Etodolac |
author_facet |
Liao Kuan-Fu Cheng Kao-Chi Lin Cheng-Li Lai Shih-Wei |
author_sort |
Liao Kuan-Fu |
title |
Etodolac and the risk of acute pancreatitis |
title_short |
Etodolac and the risk of acute pancreatitis |
title_full |
Etodolac and the risk of acute pancreatitis |
title_fullStr |
Etodolac and the risk of acute pancreatitis |
title_full_unstemmed |
Etodolac and the risk of acute pancreatitis |
title_sort |
etodolac and the risk of acute pancreatitis |
publisher |
China Medical University |
series |
BioMedicine |
issn |
2211-8039 |
publishDate |
2017-03-01 |
description |
Objective: The aim of this study was to explore the association between etodolac use and acute in Taiwan.
Design: We designed a case-control study using the database of Taiwan’s National Health Insurance.
Subjects: In all, 7577 subjects aged 20 years or older with newly diagnosed acute pancreatitis were defined as cases, and 27032 sex-matched and age-matched subjects without acute pancreatitis were defined as controls. The period considered for this study was from 1998 to 2011. For the study, never having used etodolac is defined as a subject never receiving a prescription for etodolac. Active use of etodolac is defined as a subject receiving at least 1 prescription for etodolac within 7 days of the date of their being diagnosed with acute pancreatitis. Non-active use of etodolac is defined as a subject not receiving a prescription for etodolac within 7 days but receiving at least 1 prescription for etodolac ≥ 8 days before the date of their being diagnosed with acute pancreatitis.
Main outcome measure: The association between etodolac use and acute pancreatitis was estimated by using the multivariable unconditional logistic regression model.
Results: After correcting for covariates, the adjusted odds ratio of acute pancreatitis was 3.78 for subjects with active use of etodolac (95% confidence interval 1.11, 12.9), compared with subjects who never used etodolac. The adjusted odds ratio decreased to 1.18 for subjects with non-active use of etodolac (95% confidence interval 0.38, 3.67), but that was without statistical significance.
Conclusion: There could be an association between active use of etodolac and acute pancreatitis. Clinicians should take into account the possibility of etodolac-associated acute pancreatitis when patients currently using etodolac present with acute pancreatitis with an unknown cause. |
topic |
Acute pancreatitis Etodolac |
url |
https://doi.org/10.1051/bmdcn/2017070104 |
work_keys_str_mv |
AT liaokuanfu etodolacandtheriskofacutepancreatitis AT chengkaochi etodolacandtheriskofacutepancreatitis AT linchengli etodolacandtheriskofacutepancreatitis AT laishihwei etodolacandtheriskofacutepancreatitis |
_version_ |
1724518117879578624 |